<PAGE>


Exhibit 99.4

MIV THERAPEUTICS SUCCESSFULLY COMPLETES GOVERNMENT-SPONSORED DRUG-ELUTING STENT
COATING R&D PROGRAM

Tuesday February 10, 9:30 am ET

VANCOUVER, British Columbia, Feb. 10 /PRNewswire-FirstCall/ -- MIV Therapeutics
Inc. (OTC Bulletin Board: MIVT; BSE: MIV; Frankfurt: MIV1) is pleased to
announce that it has successfully completed the first phase of its
Hydroxyapatite (HA) Drug-Eluting Stent Coating R&D Program sponsored in part by
the Canadian Government. The University of British Columbia has submitted its
final report to the Natural Sciences and Engineering Research Council of Canada
(NSERC) which provided a grant in support of the research program entitled
"Functionally Gradient Calcium Phosphate Coatings for Stents." The research
activities were conducted by the University of British Columbia, UBCeram --
Metals and Materials Engineering, in close cooperation with MIVT's R&D team,
under a Collaborative Research and Development Agreement.

The objective of the program was to develop multilayer biocompatible and
bioactive calcium phosphate functionally graded coatings on stents. Two types of
coatings were developed:

     a) a thin film coating of dense, crystalline hydroxyapatite (HA) designed
        to screen the metal surface from the surrounding tissue to prevent
        inflammatory response in the tissue and to provide a high-adhesion
        surface for the second coating.

     b) a thicker, porous, film of HA. The goal was to achieve formation of an
        adhesive hydroxyapatite layer suitable for the application of drugs.

An extensive range of tests were performed to validate the reproducibility and
integrity of the above coatings, and their suitability for use on cardiovascular
stents and other medical devices, with a focus on drug encapsulation and drug
eluting applications.

Dr. Tom Troczynski, Professor of Ceramics at The University of British Columbia
Metals and Materials Engineering Department, and MIVT's Vice President of
Coatings summarized: "We have completed all the tasks related to the deposition
and evaluation of submicron film uniformity on the complex stent surface. We
have evaluated alternative methods for such film deposition as well as chemical
surface modification methods for improved surface coverage and adhesion of the
coatings. This NSERC-sponsored program resulted in the successful development of
two alternative coating technologies that produced coatings with excellent
properties, ideally suited for drug encapsulation for drug-eluting purposes."

President and CEO Alan Lindsay commented, "Completing on time this intense phase
of our comprehensive program continues our systematic advances towards the
successful commercialization of our coating technologies for the treatment of
cardiovascular disease. We are continuing to aggressively pursue our R&D
program, in accordance with the stringent requirements of our industry and in
line with our extremely demanding schedule. We recently reported on the
successful completion of the fatigue life testing performed by Minnesota-based
EnduraTEC Testing Services Inc., that provided solid proof of the robustness of
our coating technology. In addition, a comprehensive range of tests required by
both CE Mark and FDA regulatory bodies are either in progress or are planned for
the very near future."

Vice President Operations, Arc Rajtar, added: "In spite of the challenges which
are inevitably associated with developing leading edge technologies, our
ambitious research and development program has consistently achieved all the
critical milestones on schedule. NSERC program started in November 2002 and
continued till the end of December 2003, with the final report supplied to NSERC
recently. The great contribution of the UBC scientists, the exemplary
cooperation between the MIVT and UBC teams, and our continued focus on
objectives have allowed us to progress successfully to the next stage of our R&D
program."

About University of British Columbia
UBC, located in the Pacific Rim gateway of Vancouver, Canada, ranks in the top
10 of North American universities in technology licensing and commercialization,
and generates more U.S. patents than any other Canadian public institution.

<PAGE>

About MIV Therapeutics

MIV Therapeutics is developing a "next generation" line of advanced
biocompatible coatings for stents and medical devices. The HAp coating
technology has successfully passed animal trials focused on thrombogenicity
(blood-clotting) and demanding fatigue life testing that simulated the radial
strain produced by heartbeats in a coronary artery. MIV's ultra-thin coating has
been designed to inhibit inflammatory response. A Collaborative Research
Agreement between MIVI and the University of British Columbia has received a
research and development grant from the Natural Sciences and Engineering
Research Council of Canada (NSERC) for the development of HAp as a drug eluting
coating. MIVT's manufacturing facility maintains a comprehensive QA (Quality
Assurance) system that meets the guidelines applicable to CE Mark, FDA and GMP
requirements. Please visit www.mivtherapeutics.com for more information.


     Investor Inquiries:
     Patrick McGowan
     pmcgowan@mivtherapeutics.com
     ----------------------------
     Ph: (604) 301-9545 ext. 11
     Fax: (604) 301 9546

     Product inquiries and business opportunities:
     Arc Rajtar
     arajtar@mivi.ca
     ---------------
     (604) 301-9545 ext 22

Except for the historical information contained herein, the matters discussed in
this press release are forward-looking statements. Such statements are indicated
by words or phrases such as "believe," "will," "breakthrough," "significant,"
"indicated," "feel," "revolutionary," "should," "ideal," "extremely" and
"excited." These statements are made under "Safe Harbor" provisions of the
Private Securities Litigation Reform Act of 1995. Actual results may differ
materially from those described in forward-looking statements and are subject to
risks and uncertainties. See the Company's filings with the Securities and
Exchange Commission including, without limitation, the Company's recent Form
10-K and Form 10-Qs, which identify specific factors that may cause actual
results or events to differ materially from those described in the
forward-looking statements.